Global Postmenopausal Osteoporosis Drugs Market 2016-2020 - Emergence of Novel Agents - Key Vendors are Amgen, Merck & Novartis - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global

Postmenopausal Addiction Programs Osteoporosis Drugs Market 2016-2020" report to

their offering.

The report forecasts the Global Postmenopausal Osteoporosis Drugs Market

to grow at a CAGR of 4.02% during the period 2016-2020.

A trend to watch in the postmenopausal osteoporosis drugs market is the

emergence of novel agents. There have been encouraging developments in

the postmenopausal osteoporosis drug pipeline. Novel agents may offer

superior benefit-risk profiles and improved safety profiles compared

with conventional treatment options. Many drugs have obtained approval

while others are in different phases of development.

According to the report, a key growth driver for this market is the

growing prevalence of postmenopausal osteoporosis. The average life

expectancy for women is estimated to be around 73 years, which increases

the risk of developing postmenopausal osteoporosis. During menopause,

the amount of estrogen in the body declines, resulting in osteoporosis.

According to the World Health Organization (WHO), osteoporosis is second

only to cardiovascular disease as a global healthcare problem. It is

estimated that Methadone over 200 million people worldwide have this disease, and

this number is increasing considerably. It is estimated that 30% of all

the women in the postmenopausal stage have postmenopausal osteoporosis

in the US and Europe.

Further, the report states that one challenge that could hinder market

growth is the low diagnosis rate of postmenopausal osteoporosis.

Referred to as a silent disease, the patient remains unaware of it until

it has progressed to the higher stages.

Key vendors:

Eli Lilly




Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Key buying criteria

PART 07: Pipeline scenario

PART 08: Market landscape

PART 09: Market segmentation by therapeutic class

PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

For more information visit

Write a comment

Comments: 0

This is the sidebar.



This section is visible on every page of your website. The sidebar is a great place to put important information like contact details, store hours, or social media links. If you build an online store, the shopping cart will appear here.